Lifileucel (lifileucel)
Iovance Biotherapeutics · Tumor-Infiltrating Lymphocyte (TIL) Therapy
What is Lifileucel? Lifileucel (brand: Amtagvi) is the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy, approved for adult patients with unresectable or metastatic melanoma who have received prior treatment with a PD-1/PD-L1 blocking antibody and a BRAF inhibitor (if BRAF V600 mutation positive).
About Lifileucel
| Brand Name | Lifileucel |
| Generic / INN | lifileucel |
| Drug Class | Tumor-Infiltrating Lymphocyte (TIL) Therapy |
| Manufacturer | Iovance Biotherapeutics |
| Administration | IV infusion (autologous, patient-specific) |
| FDA Approval | 2024 |
FDA-Approved Uses for Lifileucel
Indications are based on FDA approval. Your healthcare provider determines appropriate use based on your specific diagnosis, stage, biomarker status, and overall clinical picture.
- Unresectable or metastatic melanoma — adult patients after prior treatment with a PD-1/PD-L1 checkpoint inhibitor and a BRAF inhibitor (if BRAF V600 mutation-positive)
How Does Lifileucel Work?
Lifileucel consists of tumor-infiltrating lymphocytes (TILs) — immune cells naturally present within the patient's own tumor. TILs are harvested from a resected tumor fragment, expanded ex vivo to large numbers (up to billions of cells), and infused back into the patient after lymphodepleting chemotherapy. The expanded TILs have diverse natural T-cell receptors recognizing tumor-specific antigens and attack melanoma cells without genetic engineering.
Dosage & Administration
Single IV infusion following non-myeloablative lymphodepleting chemotherapy (fludarabine + cyclophosphamide), then high-dose interleukin-2 (aldesleukin) after infusion. The number of cells infused is patient-specific (minimum 7.5 × 10⁹ viable cells). The full process takes approximately 5–7 weeks from tumor harvest to infusion.
Dosing is individualized by the prescribing clinician. Never adjust your dose without consulting your healthcare provider. This information is educational only and does not replace the official prescribing information.
Warnings, Precautions & Side Effects
General Warning
Cytokine release syndrome (CRS). Prolonged severe cytopenias. Severe infections. Prolonged immune deficiency. Respiratory failure. High-dose IL-2 toxicity (required post-infusion): capillary leak syndrome, hypotension, pulmonary edema. Neurological toxicity. Available only at certified healthcare facilities.
- Cytokine release syndrome
- Prolonged severe cytopenias
- Severe infections
- Respiratory failure
- High-dose IL-2 capillary leak syndrome
- Neurological toxicity
Common Side Effects
- CRS
- Prolonged cytopenias
- Infections
- Nausea
- Fatigue
- IL-2 toxicity effects
- Hypotension
This is not a complete list. Always report new or worsening symptoms to your healthcare provider promptly.
Storage & Handling
Cryopreserved product — stored in liquid nitrogen vapor phase (≤ −130°C). Must be shipped and handled under validated cryogenic conditions.
BiologicHealthPlus provides temperature-monitored cold-chain specialty delivery for medications requiring refrigeration. Never use a medication if its storage conditions have been compromised.
Insurance Coverage, Prior Authorization & Patient Assistance
🛡️ Commercial Insurance
Lifileucel is covered by most major commercial insurance plans when medically necessary and prior authorized. Coverage tier and cost-sharing vary by plan.
✅ Prior Authorization
Prior authorization is required by virtually all insurance plans for Lifileucel. BiologicHealthPlus handles the complete prior authorization process at no cost to patients or providers.
🏥 Medicare Coverage
Medicare Part B covers this IV medication when administered in a clinical setting. Medicaid coverage varies by state.
🆓 Patient Assistance
Manufacturer patient assistance programs may be available for eligible uninsured or underinsured patients. Contact BiologicHealthPlus for a confidential eligibility review.
Prior Authorization Patient Assistance Insurance & Savings Medication Costs
Frequently Asked Questions — Lifileucel
Lifileucel (Amtagvi) is the first FDA-approved tumor-infiltrating lymphocyte (TIL) therapy, approved in 2024 for unresectable or metastatic melanoma after prior checkpoint inhibitor therapy (and BRAF inhibitor if BRAF-mutated).
CAR-T cells are genetically engineered to express a specific synthetic receptor targeting one antigen. TIL therapy uses the patient's own naturally occurring tumor-reactive T cells — harvested from the tumor itself — which have diverse natural T-cell receptors and can recognize multiple tumor antigens simultaneously.
High-dose interleukin-2 (IL-2/aldesleukin) is given after the TIL infusion to expand and sustain the infused lymphocytes. IL-2 causes significant toxicities (capillary leak, hypotension) that require intensive monitoring at certified facilities.
As a 2024 FDA approval, coverage is still being established across plans. Prior authorization with full documentation of prior therapy (checkpoint inhibitor + BRAF inhibitor if applicable) is required. BiologicHealthPlus assists with access coordination.
Related Medications & Conditions
Related Medications
Keytruda (pembrolizumab) · Opdivo (nivolumab) · Tafinlar + Mekinist (BRAF/MEK) · Yescarta · Abecma
Related Conditions
Unresectable melanoma · Metastatic melanoma · Advanced skin cancer